U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Mariska Hargitay Partners with Bristol Myers Squibb for "Investigating Myeloma" Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD?L1/VEGF?A Bispecific Immunomodulator to Treat Kidney Cancer
Izalontamab Brengitecan Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb Announces Opdivo® in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
